Attached files

file filename
8-K - FORM 8-K CURRENT REPORT - SIGMA LABS, INC.f8k032917_8k.htm


[f8k032917_ex99z1001.jpg]


Sigma Labs Announces Full Year 2016 Financial Results


Recent Steps Position Company for Next Phase of Growth


SANTA FE, N.M. – March 30, 2017 – Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced financial results for the three and twelve months ended December 31, 2016.


Recent Highlights


Completed a public offering that raised gross proceeds of approximately $5.8 million concurrent with uplisting to the NASDAQ Capital Market following a reverse stock split. The offering provided funds for the Company’s 2017 growth plans, while moving to the NASDAQ allows for a broader base of potential institutional investors.


The Company also formed strategic alliances with Morf3D and Jaguar Precision Machine (“Jaguar”) to serve the additive manufacturing (“AM”) needs of the aerospace and defense (“A&D”) sector. As part of these agreements, the Company’s PrintRite3D® software will be licensed to Morf3D and Jaguar, and Sigma Labs will utilize its on-site EOS machine to form aerospace components under contract using additive manufacturing. The strategic alliances are expected to significantly enhance the Company’s 2017 top line growth profile.


Sigma Labs announced additional contract wins with Aerojet Rocketdyne, Pratt & Whitney, Honeywell, and Siemens during the fourth quarter and early part of 2017.


The Company also announced, subsequent to the end of 2016, that a leading European AM equipment provider had signed onto its OEM Partner Program as part of a long-term commercial agreement, expanding an existing relationship. Sigma Labs’ PrintRite3D® applications will be embedded in certain of the OEM’s AM machines prior to them being sold.


“We’re already well into 2017 and, with so much behind us, I feel the Company is in a position to see greatly improved performance going forward,” said Mark Cola, President & CEO of Sigma Labs. “In a relatively short period of time we’ve raised much-needed growth capital, uplisted to the NASDAQ, signed several important strategic relationships, and won contracts with marquee customers such as Pratt & Whitney and Siemens. We’ve also landed a significant OEM Partner and are actively working on other business development initiatives, setting the stage for stronger growth in the quarters to come. In effect, we’ve done what we said we would do – winning new customers, joining with other leading companies to move the industry forward, and improving our balance sheet to take advantage of the opportunities to come. This year we have the wind at our backs, with unlimited potential for taking additive manufacturing to a whole new level.”


2016 Full Year Financial Results


Revenue for the year ended December 31, 2016 was approximately $1.0 million versus approximately $1.2 million for 2015. The Company reported a net loss for the year of approximately $2.2 million, or $(0.35) per diluted share, versus a loss of approximately $1.7 million, or $(0.27) per diluted share, for 2015.


Investor Conference Call


The Company will host a conference call to discuss its 2016 full year financial results today, March 30, 2017, at 11:00 a.m. Eastern Time. To participate in the call, please dial toll free 1-844-802-2441, or 1-412-317-5134, approximately five minutes before the conference call time stated above. A live webcast of the call can also be accessed on the Sigma Labs website at www.sigmalabsinc.com. A recording will be available on the Company's website upon completion of the call.





About Sigma Labs, Inc.


Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in our annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.


Investor Relations Contact:


Chris Witty

cwitty@darrowir.com; 646-438-9385


















Sigma Labs, Inc.

Condensed Statements of Operations



 

 

Three Months Ended

 

Twelve Months Ended

 

 

Years Ended December 31

 

Years Ended December 31

 

 

2016

 

2015

 

2016

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

$

324,192

$

586,295

$

966,422

$

1,234,810

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

21,158

 

75,625

 

228,902

 

214,004

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

303,034

 

510,670

 

737,520

 

1,020,806

 

 

 

 

 

 

 

 

 

EXPENSES:

 

 

 

 

 

 

 

 

Other General and Administration

 

444,520

 

395,987

 

1,790,096

 

1,282,952

Payroll Expense

 

299,346

 

247,173

 

1,026,840

 

585,706

Stock-Based Compensation

 

105,004

 

39,938

 

341,558

 

518,438

Research and Development

 

4,488

 

124,009

 

92,992

 

330,554

Total Expenses

 

853,358

 

807,107

 

3,251,486

 

2,717,650

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

Interest Income

 

67

 

203

 

355

 

1,340

Other Income

 

20,077

 

-

 

51,703

 

-

Other Income-Decrease in fair value of derivative liabilities

 

354,644

 

-

 

354,644

 

-

Other Expense - Debt discount amortization

 

(89,570)

 

-

 

(89,570)

 

 

Loss on Investment in Joint Venture

 

105

 

(670)

 

-

 

(778)

Total Other Income

 

285,323

 

(467)

 

317,132

 

562

 

 

 

 

 

 

 

 

 

LOSS BEFORE PROVISION FOR INCOME TAXES

 

(265,001)

 

(296,904)

 

(2,196,834)

 

(1,696,282)

 

 

 

 

 

 

 

 

 

Provision for income Taxes

 

-

 

-

 

-

 

-

 

 

 

 

 

 

 

 

 

Net Loss

$

(265,001)

$

(296,904)

$

(2,196,834)

$

(1,696,282)

 

 

 

 

 

 

 

 

 

Net Loss per Common Share - Basic and Diluted

$

(0.04)

$

(0.05)

$

(0.35)

$

(0.27)

 

 

 

 

 

 

 

 

 

Weighted Average Number of Shares

 

 

 

 

 

 

 

 

  Outstanding - Basic and Diluted

 

6,267,577

 

6,237,511

 

6,249,609

 

6,228,108







Sigma Labs, Inc.

Condensed Balance Sheets



 

 

December 31, 2016

 

December 31, 2015

ASSETS

 

 

 

 

Current Assets:

 

 

 

 

Cash

$

398,391

$

1,539,809

Accounts Receivable, net

 

288,236

 

280,222

Inventory

 

187,241

 

20,129

Prepaid Assets

 

36,056

 

38,687

Total Current Assets

 

909,924

 

1,878,847

 

 

 

 

 

Other Assets:

 

 

 

 

Property and Equipment, net

 

564,933

 

714,754

Intangible Assets, net

 

226,450

 

167,644

Investment in Joint Venture

 

500

 

9,222

Prepaid Stock Compensation

 

167,562

 

418,547

Total Other Assets

 

959,445

 

1,310,167

 

 

 

 

 

TOTAL ASSETS

$

1,869,369

$

3,189,014

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 


Current Liabilities:

 

 

 

 

Accounts Payable

$

112,175

$

38,393

Notes Payable, net of original issue discount $79,886

 

561,834

 

-

Accrued Expenses

 

125,116

 

71,523

Total Current Liabilities

 

799,125

 

109,916


Long-Term Liabilities

 

 

 

 

Derivative Liability

 

93,206

 

-

Total Long-Term Liability

 

93,206

 

-

 

 

 

 

 

TOTAL LIABILITIES

 

892,331

 

109,916

 

 

 

 

 

Stockholders' Equity

 

 

 

 

Preferred Stock, $0.001 par; 10,000,000 shares authorized;

None issued and outstanding

 

-

 

-

Common Stock, $0.001 par; 15,000,000 shares authorized;

6,267,577 and 6,239,073 issued and outstanding at

December 31, 2016 and 2015, respectively

 

6,268

 

6,239

Additional Paid-In Capital

 

10,731,724

 

10,636,979

Accumulated Deficit

 

(9,760,954)

 

(7,564,120)

Total Stockholders' Equity

 

977,038

 

3,079,098

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

1,869,369

$

3,189,014